Wednesday, September 27, 2017 4:19:08 PM
Thank you for your email. We presented a company update today at the Cantor conference: http://ir.genocea.com/events.cfm
Regarding the decision to explore strategic alternatives for GEN-003, we have been in the process of seeking capital to secure financing for GEN-003 for some time now and previously announced that, if we were not able to secure such capital, we would be reviewing our strategic alternatives to maximize value.
Since the time of those disclosures, we have determined that the significant financial resources required to advance GEN-003 into a large and long Phase 3 program are beyond Genocea alone, as such we are reviewing strategic alternatives for GEN-003 as we seek the right partner to move the program forward.
Given this reality, we have had to make the hard decision to restructure our workforce and to focus on our cancer work, which leverages our core ATLAS platform technology as a potentially superior approach to neoantigen selection for next generation cancer vaccines.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM